Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (FUDANZHANGJIANG; HK:01349) has released its board-reshuffle blueprint ahead of the 2025 annual general meeting (AGM). The current eighth-session Board will conclude at the AGM, after which shareholders will vote on a new three-year term for the ninth Board.

Board Composition and Nominees • Size and Structure: The proposed ninth Board will comprise eight directors—two executive, two non-executive, three independent non-executive (INEDs) and one employee director, in line with Hong Kong and Shanghai listing rules and the company’s Articles of Association. • Executive Directors: Re-election of Chairman/General Manager Zhao Da Jun and Deputy GM/CFO Xue Yan. • Non-executive Directors: New appointment of Zhong Tao (VP & Board Secretary, Shanghai Pharmaceuticals Holding) and re-election of Yu Xiao Yang. • Independent Non-executive Directors: Re-election of Wang Hong Guang, Lam Siu Wing and Xu Pei Long. • Employee Director: Qu Ya Nan will stand for re-election at the company’s employee representatives meeting.

Departure • Incumbent non-executive director Shen Bo will retire at the 2025 AGM and will not seek re-election.

Remuneration Snapshot (FY2025) • Zhao Da Jun: RMB1.66 million (salaries, allowances and retirement benefits); holds 15.62 million A-shares (1.51% of total share capital). • Xue Yan: RMB1.49 million; holds 2.03 million shares (1.98 million A-shares and 50,000 H-shares), aggregating 0.20% of issued capital. • INEDs Wang Hong Guang, Lam Siu Wing and Xu Pei Long: Director’s fees of RMB0.20 million each. • Non-executive directors Zhong Tao and Yu Xiao Yang will receive no director’s emolument.

Governance and Compliance The Nomination Committee confirmed that the proposed slate meets regulatory and internal guidelines, including board-diversity requirements on gender, age, expertise and international experience. All INEDs have affirmed independence per Hong Kong Listing Rule 3.13.

Next Steps Shareholders will vote on the proposed appointments at the 2025 AGM. If approved, the new Board’s term will run for three years from the date of the meeting. A detailed circular will be dispatched to shareholders in due course.